Stocksigma LogoStocksigma Logo

Alembic Pharmaceuticals Secures USFDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

Alembic Pharmaceuticals received USFDA final approval on 17th Oct'26 for its ANDA Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%

Alembic Pharmaceuticals Secures USFDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

Alembic Pharmaceuticals Ltd 路 Press Release 路 18 Oct 2026, 12:22 am

Alembic Pharmaceuticals Secures USFDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension Alembic Pharmaceuticals received USFDA final approval on 17th Oct'26 for its ANDA Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%, therapeutically equivalent to Sandoz Inc.'s Ciprodex. The product is indicated for acute otitis media and acute otitis externa. Per IQVIA data, the product's estimated market size was US$110mn for the 12 months ending Jun'26. With this nod, Alembic holds a cumulative total of 246 USFDA ANDA approvals, comprising 226 final and 20 tentative approvals.

Original exchange filing (PDF)

More announcements from Alembic Pharmaceuticals Ltd

All Alembic Pharmaceuticals Ltd announcements